BACKGROUND: The clinical significance of pretransplant donor-specific antibodies (pre-Tx DSAs) detected by single-antigen bead flow cytometry (SAB-FC) remains unclear. METHODS: To investigate the impact that pre-Tx DSAs detected by SAB-FC have on early clinical outcomes, we tested pre-Tx sera from all consecutive deceased-donor kidney transplants performed between January 2005 and July 2006 (n=237). RESULTS: In the study population of which 66% had a high-immunologic risk, mean fluorescence intensity (MFI) more than or equal to 100 for class I and more than or equal to 200 for class II were the lowest DSA thresholds associated with inferior antibody-mediated rejection-free graft survival (75% vs. 90%, P=0.004 and 76% vs. 87%, P=0.017, respectively). The hazard ratio for antibody-mediated rejection increased linearly with higher class II DSA from MFI 100 to 800 (1.7[0.8-3.2], P=0.1 for MFI ≥100 vs. 4.7[2.4-8.8], P<0.001 for MFI ≥ 800). Differences in graft function were only evident in patients with class II MFI more than or equal to 500 (estimated glomerular filtration rate: 47.6 vs. 54.3, P=0.02 and proteinuria: 0.6 ± 0.6 vs. 0.4 ± 0.3, P=0.03). A difference in death-censored graft survival was detected in patients with class II MFI more than or equal to 1000 (75% vs. 91.9%, P=0.055). CONCLUSION: High-pre-Tx DSAs detected by SAB-FC are associated with incrementally poor graft outcomes in deceased-donor kidney transplant with high-immunologic risk.
BACKGROUND: The clinical significance of pretransplant donor-specific antibodies (pre-Tx DSAs) detected by single-antigen bead flow cytometry (SAB-FC) remains unclear. METHODS: To investigate the impact that pre-Tx DSAs detected by SAB-FC have on early clinical outcomes, we tested pre-Tx sera from all consecutive deceased-donor kidney transplants performed between January 2005 and July 2006 (n=237). RESULTS: In the study population of which 66% had a high-immunologic risk, mean fluorescence intensity (MFI) more than or equal to 100 for class I and more than or equal to 200 for class II were the lowest DSA thresholds associated with inferior antibody-mediated rejection-free graft survival (75% vs. 90%, P=0.004 and 76% vs. 87%, P=0.017, respectively). The hazard ratio for antibody-mediated rejection increased linearly with higher class II DSA from MFI 100 to 800 (1.7[0.8-3.2], P=0.1 for MFI ≥100 vs. 4.7[2.4-8.8], P<0.001 for MFI ≥ 800). Differences in graft function were only evident in patients with class II MFI more than or equal to 500 (estimated glomerular filtration rate: 47.6 vs. 54.3, P=0.02 and proteinuria: 0.6 ± 0.6 vs. 0.4 ± 0.3, P=0.03). A difference in death-censored graft survival was detected in patients with class II MFI more than or equal to 1000 (75% vs. 91.9%, P=0.055). CONCLUSION: High-pre-Tx DSAs detected by SAB-FC are associated with incrementally poor graft outcomes in deceased-donor kidney transplant with high-immunologic risk.
Authors: J G O'Leary; H Kaneku; B M Susskind; L W Jennings; M A Neri; G L Davis; G B Klintmalm; P I Terasaki Journal: Am J Transplant Date: 2011-06-14 Impact factor: 8.086
Authors: Dinesh Kannabhiran; John Lee; Joseph E Schwartz; Rex Friedlander; Meredith Aull; Thangamani Muthukumar; Sean Campbell; David Epstein; Surya V Seshan; Sandip Kapur; Vijay K Sharma; Manikkam Suthanthiran; Darshana Dadhania Journal: Transplantation Date: 2015-06 Impact factor: 4.939
Authors: Laura Pankhurst; Alex Hudson; Lisa Mumford; Michelle Willicombe; Jack Galliford; Olivia Shaw; Raj Thuraisingham; Carmelo Puliatti; David Talbot; Sian Griffin; Nicholas Torpey; Simon Ball; Brendan Clark; David Briggs; Susan V Fuggle; Robert M Higgins Journal: Transplant Direct Date: 2017-06-26
Authors: Arjang Djamali; Brenda L Muth; Thomas M Ellis; Maha Mohamed; Luis A Fernandez; Karen M Miller; Janet M Bellingham; Jon S Odorico; Joshua D Mezrich; John D Pirsch; Tony M D'Alessandro; Vijay Vidyasagar; R Michael Hofmann; Jose R Torrealba; Dixon B Kaufman; David P Foley Journal: Kidney Int Date: 2013-02-27 Impact factor: 10.612